Uveitis is not technically a rare disease, though it’s uncommon enough that many people never encounter it. In the United States, the legal definition of a rare disease is one that affects fewer than 200,000 people. Uveitis exceeds that threshold significantly, with population-based estimates suggesting a prevalence of roughly 115 to 540 per 100,000 people, translating to hundreds of thousands of affected Americans at any given time. It’s uncommon, but it’s far more widespread than most people assume, and it accounts for up to 20% of legal blindness worldwide.
How Common Uveitis Actually Is
Estimates of uveitis prevalence vary depending on how researchers count cases, but all of the major studies place it well above the rare disease cutoff. Earlier U.S. studies found a prevalence of about 115 to 121 cases per 100,000 adults. A more recent nationally representative analysis using federal health survey data estimated a higher figure: 5.4 per 1,000 residents, or 540 per 100,000. Even when that study restricted its count to only patients who had received treatment (a stricter way of confirming diagnosis), the number was still 340 per 100,000.
The gap between these estimates likely reflects differences in methodology. The older studies relied on insurance claims and medical records, which miss undiagnosed or untreated cases. The newer survey captured self-reported diagnoses across a broader population. The true number probably falls somewhere in between, but either way, uveitis affects a large enough portion of the population that eye specialists encounter it regularly.
Uveitis in Children Is Genuinely Uncommon
While uveitis overall isn’t rare, pediatric uveitis is much less common. Children account for only 5% to 10% of all uveitis cases, with an incidence of about 4 per 100,000 children and a prevalence of 28 per 100,000. That puts it closer to rare disease territory for the pediatric population specifically.
Childhood uveitis also behaves differently. More than half of cases in children have no identifiable cause, a higher proportion than in adults. Some forms of uveitis are seen almost exclusively in children, particularly the type linked to juvenile idiopathic arthritis. Because the condition is less expected in young patients, it can be missed or misdiagnosed, making awareness especially important for parents and pediatricians.
The Four Types and Their Frequency
Uveitis is classified by which part of the eye is inflamed, and the types vary considerably in how often they occur. The most common form, anterior uveitis, affects the front of the eye (mainly the iris) and makes up about 38% of cases. This is the type most people picture when they think of uveitis: a red, painful eye with light sensitivity that often responds well to treatment.
Posterior uveitis, which involves the back of the eye including the retina and the tissue beneath it, accounts for roughly 28% of cases. Intermediate uveitis, affecting the gel-like substance in the middle of the eye, makes up about 13%. Panuveitis, where inflammation spans the entire eye, represents around 11%. The remaining cases are caused by direct trauma to the eye.
Posterior uveitis and panuveitis tend to be more serious because they threaten the structures most critical for vision. They’re also harder to detect early since they don’t always produce the obvious redness and pain that anterior uveitis does.
Why It Often Takes Years to Get Diagnosed
One reason uveitis flies under the radar is that it’s frequently misdiagnosed or diagnosed late. The average time between a person’s first eye symptoms and their first evaluation by a uveitis specialist is just over two years. In some cases, the delay stretches to nearly 20 years. Once a patient does reach a specialist, diagnosis typically happens within about five weeks, suggesting the bottleneck isn’t the complexity of diagnosis itself but the referral process.
Part of the problem is that uveitis symptoms, particularly eye redness, blurred vision, and pain, overlap with more common conditions like conjunctivitis or dry eye. General practitioners and even general ophthalmologists may not immediately suspect uveitis, especially in patients without known autoimmune conditions. That delay matters: untreated or undertreated uveitis can cause permanent damage including cataracts, glaucoma, and vision loss.
What Causes It
Uveitis has dozens of potential triggers, broadly split into infectious and non-infectious categories. Infectious causes include viruses like herpes simplex and varicella zoster, as well as bacteria that cause tuberculosis and syphilis. The parasite responsible for toxoplasmosis is another well-known trigger, particularly for posterior uveitis.
Non-infectious uveitis is more common overall and is driven by the immune system attacking the eye’s own tissue. It can occur on its own with no identifiable cause, which doctors classify as “undifferentiated” uveitis. It can also be linked to systemic autoimmune or inflammatory conditions. The most frequently associated diseases include ankylosing spondylitis (a type of inflammatory spinal arthritis), sarcoidosis, Behçet disease, and multiple sclerosis. In children, juvenile idiopathic arthritis is the leading associated condition. When uveitis is connected to one of these diseases, it’s typically called “disease-associated” uveitis, and treating the underlying condition is often key to controlling the eye inflammation.
How It’s Treated
Treatment follows a stepwise approach. For mild anterior uveitis, steroid eye drops are usually enough to calm inflammation. Many people with a single episode of anterior uveitis recover fully and never have another flare.
When inflammation is more severe, recurrent, or located deeper in the eye, oral steroids become necessary. But steroids carry significant side effects when used long term, including weight gain, bone thinning, elevated blood sugar, and ironically, the eye complications (cataracts and glaucoma) that uveitis itself can cause. So the goal is always to get patients off steroids as quickly as possible.
The next step involves immune-suppressing medications that reduce the body’s inflammatory response more broadly. These can take weeks to months to reach full effect but allow patients to taper off steroids. For people whose uveitis doesn’t respond to these conventional options, biologic therapies offer a newer alternative. These are targeted drugs that block specific parts of the immune response. In studies of patients with stubborn, treatment-resistant uveitis, biologics achieved remission rates of 50% by about four months and 70% by roughly ten months. For uveitis linked to Behçet disease, one study found improvement in nearly 80% of patients within ten weeks. Treatment failure rates dropped significantly when biologics were added to existing therapy, particularly in children with arthritis-related uveitis, where failure rates fell from 60% to 27%.
The choice of treatment depends heavily on the type of uveitis, its cause, and how many flares a person has had. Some people need treatment for only a few weeks. Others require years of maintenance therapy to prevent recurrence and protect their vision.